Davis Polk advised the underwriters in connection with the $183.9 million initial public offering of Aimmune Technologies, Inc. Aimmune Therapeutics sold 11,499,999 shares of its common stock in the offering, which included the exercise in full by the underwriters of their option to purchase up to an additional 1,499,999 shares of common stock. Aimmune’s common stock began trading on The NASDAQ Global Select Market on August 6, 2015 under the symbol AIMT.

Based in Brisbane, California, Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut allergy and other food allergies.

The Davis Polk corporate team included partners Bruce K. Dallas and Stephen Salmon and associates Mohammad Ali and Varun Natteri Mangadu. The tax team included partner Rachel D. Kleinberg and associates Isaac Macdonald, Brian Harris and Peter Benesch. The intellectual property team included associates David R. Bauer and Katharine Jan. Counsel Cynthia Akard and Marcie A. Goldstein provided executive compensation and FINRA advice, respectively. Members of the Davis Polk team are based in the Northern California and New York offices.